Cancer Research Institute

Parker Institute, Bristol-Myers Squibb, Cancer Research Institute collaborate

Wednesday, March 29, 2017

The Parker Institute for Cancer ImmunotherapyBristol-Myers Squibb and the Cancer Research Institute (CRI) have announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely with Parker Institute and CRI scientists and researchers, soliciting clinical research proposals from their networks and coordinating multi-site collaboration clinical studies to pursue some of the most difficult questions in cancer research. It will provide scientists with an ecosystem of advanced translational tools, precision immunotherapy and cutting-edge bioanalytical expertise to maximize learning and ensure the generation of high quality data to inform future development.

[Read More]

CRI and Cancer Immunology

Monday, April 27, 2015

The Pulse on Global Trials by Matthew Howes

Since being named “Breakthrough of the Year” by Science magazine less than two years ago, cancer immunology has been taken from the fringe to the forefront. 

[Read More]

Clinical Trials and the Wisdom of Crowds

Monday, December 22, 2014

The Pulse on Global Trials by Matthew Howes

I am writing this column from Basel, Switzerland, where I have been asked to share my experiences in leading innovation with an audience of 300 Roche employees.

[Read More]